Treatment Patterns and Survival Among Adult Patients With Advanced Soft Tissue Sarcoma

Share on: 

Soft tissue sarcoma (STS) is a rare group of malignant tumors comprising more than 50 histologic subtypes that are derived from connective tissues and other cells of mesenchymal origin. They account for approximately 1% of all incident malignancies.

Although there are curative surgical options for early-stage STS, treatment goals for advanced STS are more limited and are generally focused on palliative rather than curative care. We conducted a study to evaluate treatment patterns and survival among patients with advanced STS not amenable to surgery or radiotherapy, overall and by histologic subtype. Data were gathered from medical records in real-world clinical settings in the United Kingdom, Spain, Germany, and France.

The study found that patients were generally treated consistently with established treatment guidelines. Variations in treatment patterns across countries were evident, but most regimens involved the use of anthracyclines; doxorubicin, alone or in combination with ifosfamide, was the most common first-line therapy. 

Median overall survival across all histologic subtypes was less than 2 years, indicating a continuing, critical need for advances in therapeutic options for this difficult-to-treat disease.

Treatment patterns and survival among adult patients with advanced soft tissue sarcoma: a retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. Nagar S, Mytelka D, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin J, Kaye JA.

Related Services:
Staff Members: